secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2023-06-08T23:59:59+00:00
Accession:  0001628280-23-021539
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Vanda shareholders elect directors, ratify auditor, approve say-on-pay and equity plan amendment at 2023 annual meeting
--------------------------------------------------------------------------------

- Re-elected Richard W. Dugan (43.4M for) and Anne Sempowski Ward (47.1M for) as Class II directors.
- Ratified PricewaterhouseCoopers LLP as independent auditor for FY2023 with 52.0M votes for.
- Approved non-binding advisory vote on named executive officer compensation with 47.0M votes for.
- Set future say-on-pay frequency to once every 1 year (44.6M votes for 1 year).
- Approved amendment to 2016 Equity Incentive Plan to increase authorized shares (43.7M for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828023021539/0001628280-23-021539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828023021539/vnda-20230608.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-021539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer